Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer

DOI Web Site 31 References Open Access
  • Hiroyasu Tamamura
    Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
  • Kenkei Hasatani
    Department of Gastroenterology, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
  • Sae Matsumoto
    Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
  • Satoko Asahi
    Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
  • Hitoshi Tatebe
    Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
  • Yoshitaka Sato
    Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
  • Keiichiro Matsusita
    Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
  • Yuji Tameshige
    Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
  • Yoshikazu Maeda
    Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
  • Makoto Sasaki
    Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
  • Shigeyuki Takamatsu
    Department of Radiotherapy, Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, Japan
  • Kazutaka Yamamoto
    Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan

Abstract

<jats:p>We evaluated elective nodal irradiation (ENI) doses during radical chemoradiotherapy (CRT) for esophageal cancer (EC). A total of 79 patients (65 men and 14 women) aged 52–80 years with T1-3, N0-3, and M0 (including M1ly) who underwent CRT for EC during November 2012–September 2019 were eligible for this retrospective analysis. Patients were divided into two groups: the high-dose group (HG), including 38 patients who received ≥40 Gy as ENI; and the low-dose group (LG), including 41 patients who received <40 Gy. The median doses were 40.0 and 36.0 Gy in HG and LG, respectively. During the follow-up (median: 36.7 months), no lymph node recurrence was observed in the ENI field in all patients. Lymph node recurrence near the ENI field was observed in six patients. No significant differences were observed between the two groups in median overall survival, progression-free survival, and local control. Grade 3–4 acute and late adverse events were observed in five patients of HG and six patients of LG, respectively. No ulceration or stricture was observed in the ENI field on endoscopy examined with 58 Gy irradiation. In conclusion, an ENI dose of 36 Gy could be considered to control the elective nodes of EC.</jats:p>

Journal

  • Cancers

    Cancers 15 (3), 860-, 2023-01-30

    MDPI AG

References(31)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top